“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Source:
techcrunch
August 29, 2026 · 10:36
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
The original article opens on the publisher's website.
More from Automotive
View topic →Larry Page’s flying car company Pivotal loses its CEO
techcrunch
Sep 1, 2026 · 16:59
SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading
coinDesk
Sep 1, 2026 · 16:55
The Range Rover Electric: Specs, Price, Availability
wired
Sep 1, 2026 · 16:01
North Carolina Rep. Chuck Edwards is formally censured over harassment allegations
nprNews
Sep 1, 2026 · 15:18
AfterQuery reportedly becomes Y Combinator’s fastest-ever unicorn, now valued at $3.2B
techcrunch
Sep 1, 2026 · 15:08